Five defensin peptides (holosins 1-5) were identified from the Australian paralysis tick, with holosins 2 and 3 showing strong antibacterial and antifungal activity at low concentrations.
5 µM stops fungal growthHolosins 2 and 3 abrogated growth of Fusarium and Candida at just 5 µM concentration, demonstrating potent antifungal activity alongside antibacterial effects
What the researchers found
Five unique defensin sequences (holosins 1-5) were identified from the I. holocyclus transcriptome, all sharing conserved molecular features with other tick defensins including the γ-core motif.
Antimicrobial testing showed:
- Holosins 2 and 3 were very active against Gram-positive bacteria S. aureus and Listeria grayi
- Holosins 2 and 3 also killed the fungus Fusarium graminearum and yeast Candida albicans, with 5 µM sufficient to abrogate growth
- Synthetic γ-cores (HoloTickCores 1-4) generally showed lower activity than mature defensins
- Exception: HoloTickCore 2 had activity comparable to mature holosin 2 against the Gram-negative bacterium E. coli
This reveals a multigene defensin family in I. holocyclus with broad-spectrum antimicrobial activity.
Why it matters
As antibiotic resistance grows, finding new antimicrobial compounds is urgent. Ticks survive in pathogen-rich environments thanks partly to their defensin peptides, making them a rich source of potential new antimicrobials. These tick-derived peptides with broad-spectrum activity against bacteria and fungi could inspire next-generation anti-infective drugs.
How the study worked
The I. holocyclus transcriptome was searched bioinformatically for defensin sequences. Five unique sequences were identified and characterized. Holosins 2 and 3 and the predicted γ-core peptides (HoloTickCores 1-4) were synthesized and tested for antimicrobial activity against Gram-positive bacteria (S. aureus, L. grayi), Gram-negative bacteria (E. coli), fungus (F. graminearum), and yeast (C. albicans).
What this study cannot tell us
Only holosins 2 and 3 were fully tested as mature peptides; the antimicrobial profiles of holosins 1, 4, and 5 remain incomplete. All testing was in vitro — no animal or human toxicity or efficacy studies were conducted. The mechanisms of action beyond membrane disruption were not fully characterized. Stability and bioavailability of these peptides are unknown.
How to read the evidence
This is an in vitro discovery study identifying and characterizing novel peptides. The antimicrobial activity data is solid for initial characterization, but no in vivo or clinical evidence exists for these peptides.
When this study was published
Published in 2019, this study contributes to the ongoing effort to catalogue and characterize antimicrobial peptides from diverse organisms as potential sources of new anti-infective agents.
The bigger picture
This study is part of a broader effort to mine nature's biodiversity for antimicrobial peptides. Arthropods like ticks have evolved potent immune defenses over millions of years, and their defensin peptides represent largely untapped resources for addressing the growing antibiotic resistance crisis.
Questions still open
- Could holosins be effective against antibiotic-resistant strains like MRSA?
- What makes HoloTickCore 2 uniquely active against Gram-negative bacteria while other cores are not?
- Can these tick defensins be modified to improve stability for pharmaceutical development?
Common questions
What are defensins and why are they found in ticks?
Could tick peptides become new antibiotics?
Read the original research
Antibacterial and antifungal activity of defensins from the Australian paralysis tick, Ixodes holocyclus.
Ticks and tick-borne diseases, 10(6), 101269
Citation
Cabezas-Cruz, Alejandro; Tonk, Miray; Bleackley, Mark R; Valdés, James J; Barrero, Roberto A; Hernández-Jarguín, Angélica; Moutailler, Sara; Vilcinskas, Andreas; Richard-Forget, Florence; Anderson, Marilyn A; Rodriguez-Valle, Manuel. (2019). Antibacterial and antifungal activity of defensins from the Australian paralysis tick, Ixodes holocyclus.. Ticks and tick-borne diseases, 10(6), 101269. https://doi.org/10.1016/j.ttbdis.2019.101269